2014 Preliminary Results Replay
You have selected Encore.Encore is InterCall’s recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen… Read More
Oxford BioMedica: Preliminary results for the year ended 31 December 2014
Oxford, UK – 13 March 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today announces its preliminary results for the twelve months ended 31 December 2014. Read More
Oxford BioMedica: Notice of Preliminary Results
Results date: – 13 March 2015: Oxford, UK – 6 March 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Company”) a leading… Read More
Oxford BioMedica Announces Presentation at 27th Annual ROTH Conference
Oxford, UK – 5 March 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, announces that Tim Watts, Chief Financial Officer, will present a company overview on 9… Read More
Oxford BioMedica to Participate in Credit Suisse’s Global Healthcare One-on-One Conference
London, UK – 3 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:Oxford Biomedica), a leading gene and cell therapy company, announces that John Dawson, Chief Executive Officer, and Tim Watts, Chief Financial Officer, will participate… Read More
Chief Secretary to the Treasury visits Oxford BioMedica
Oxford, UK – 23 February 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, today welcomed the Rt Hon Danny Alexander, Chief Secretary to the Treasury, to its laboratories on… Read More
John Dawson, Chief Executive Officer, presented at Biotech Showcase™ 2015 Conference in San Francisco, on Monday, 12 January 2015
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present… Read More
Oxford BioMedica Interim Management Statement
Oxford, UK – 3 November 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a leading gene and cell therapy company, today publishes its interim management statement for the period from 1 July to 31… Read More
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities
Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory… Read More
Oxford BioMedica announces new process development and manufacturing collaboration which includes LentiVector® licence agreement
Oxford, UK – 10 October 2014: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which build on the… Read More
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2014
Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), a world-leading gene and cell therapy company, today announces its unaudited interim results for the six months ended 30 June 2014. Read More
Oxford BioMedica plc Directorate change
— Dr Paul Blake to take Executive Role as Chief Development Officer — Oxford, UK – 15 August 2014: Oxford BioMedica plc (LSE: Oxford Biomedica),… Read More